sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta Therapeutics stock sinks

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

Continue reading

· 23h · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

Stocktwits on MSN · 7h

Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours

FDA Shuts Down Sarepta Gene Therapy Trials

· 3h · on MSN

Sarepta to pause Elevidys gene therapy shipments in U.S.

Sarepta Therapeutics (SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, in the U.S.

Continue reading

Fierce Pharma · 18h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

· 3d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

20h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

21h

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results